CONTEXT

Multiple pathologies involving angiogenesis process have been described in the state of the art. For instance, we can mention several cancers, diabetes-linked retinopathies, arthrosclerosis, rheumatoid arthritis, psoriasis and other inflammatory diseases or pathologies linked to delayed wound healing. Many molecules have been studied for their inhibitory/activator effects on angiogenesis. Particularly, molecules with pro angiogenic activity initiated several studies in the field of cardiovascular pathologies. Indeed, promoting the development of new collateral vessels in ischemic tissues using pro angiogenic molecules (angiogenic therapy) represents a promising future for these diseases. In fact, in spite of recent progress in the prevention and treatments of ischemic cardiovascular diseases, they still are the first cause of mortality in industrialized countries. The current therapeutic strategies which aim to slow down atherosclerosis progression and to reduce the occurrence of thrombotic accidents and ischemic lesions certainly gain to efficiency but it is not sufficient to downgrade ischemic cardiovascular diseases. Another strategy consists in promoting neo vessels regeneration. However, researches carried out from now in this field lead to constrained and complex treatments such as gene therapy which sparks off ethic problems or to low efficient therapies such as the use of recombinant proteins with a low bioaccessibility after administration. There is still a need in pro angiogenic molecules, easy to synthesize and to formulate in order to allow their use as drugs for prevention and treatment of cardiovascular diseases. The present invention deals with a D-mannopyranose derivatives which avoid theses mentioned drawbacks and contains pro angiogenic activity.